BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES?